Trending News Today: Probiotics Studies Fail to Report Safety Data or Adverse Events

Top news of the day from across the health care landscape.

Roche’s investigational drug, Xofluza, showed promise in a late-stage study as a potential influenza treatment for individuals at high risk for complications, Reuters reported. According to the article, the Capstone-2 trial focused on adults aged 65 years or older, or those with conditions such as asthma, chronic lung disease, diabetes, or heart disease. The drug showed superior efficacy in speeding up improvement of symptoms compared with a placebo, the article reported.

Although probiotics are increasingly popular among consumers, a new analysis has found that many studies of probiotics fail to adequately report on safety and adverse events, STAT reported. According to the article, the study’s authors found that 37% of trials did not report safety results and 28% did not report harms-related data. Additionally, 80% of the trials did not report the number of serious problems that occurred during the study, the article noted.

A new report has found that more than 7000 Arkansas residents failed to meet the state’s new Medicaid work requirements in its first month since it took effect, The Hill reported. According to the article, the rule mandates that nonexempt beneficiaries report how they are satisfying an 80-hour per month work requirement, and those who do not meet the reporting requirement could lose their coverage. In June, 7464 residents did not meet those reporting requirements, while 445 did, the article reported.